PURPOSE The (131)I-tRRL small peptide probe has been identified in our previous study as a robust tumor molecular radiopharmaceutical that specifically binds to tumor-derived endothelial cells. In this study we developed a smaller structure cyclic tRRL (g2) radiolabeled with (99m)Tc as a novel and optimized peptide probe on tumor angiogenesis molecular imaging. METHODS Both tRRL (g2) and cont...

G1/S and G2/M cell cycle checkpoints maintain genomic stability in eukaryotes in response to genotoxic stress. We report here both genetic and functional evidence of a Gadd45-mediated G2/M checkpoint in human and murine cells. Increased expression of Gadd45 via microinjection of an expression vector into primary human fibroblasts arrests the cells at the G2/M boundary with a phenotype of MPM2 i...

This study was carried out at Sakha Animal Production Research Station, during the period from Oct., 2009 to Sept., 2010. Forty Rahmani ewes were divided into three treatment groups: the 1st, 2nd and 3rd treatment groups were intramuscularly injected (Day 0) with 1 mL GnRH analogue followed by an intramuscular injection with 0.7 mL PGF2α5 (G1), 6 (G2) or 7 (G3) days later. A second dose of 1 mL...

We have previously found that the overexpression of p53 causes G2 arrest and represses the synthesis of cyclin-dependent kinase 1 and cyclin B1, two proteins required for cells to traverse from G2 into M. G2 arrest occurs in response to DNA damage caused by a variety of agents and treatments. Here, we investigate the role of p53 in the G2 arrest that occurs in response to the topoisomerase inhi...

The hypothesis tested is that a 24-h pre-irradiation-exposure of peripheral blood lymphocytes (PBL) to the benzene metabolite hydroquinone (HQ), at doses that are non-acutely toxic (5 microM), induces a less efficient G2-M-checkpoint and enhances the G2-chromosomal radiosensitivity in a statistically significant manner (p<0.01). A less efficient G2-M-checkpoint may allow the transition of damag...

We have characterized a murine IgG monoclonal antibody, OP-G2, specific for platelet glycoprotein (GP) IIb-IIIa (alpha IIb beta 3). OP-G2 Fab fragments inhibit fibrinogen-mediated platelet aggregation and competitively inhibit adenosine diphosphate-induced binding of 125I-fibrinogen to washed platelets. OP-G2 binding to GPIIb-IIIa is specifically inhibited by RGD-containing peptides but not the...